샘플 요청 목록

 카트 문의
시장보고서
상품코드
1762359

세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 제품 유형별, 질환 적응증별, 용도별, 환자층별, 최종사용자별, 지역별, 예측(2025-2034년)

Direct Oral Anticoagulants (DOACs) Device Market Size, Share, Trends, & Industry Analysis Report By Product Type, By Disease Indication, By Application, By Patient Demographic, By End User, and By Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 130 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 직접 작용 경구용 항응고제(DOAC) 장치 시장 규모는 2034년까지 648억 3,000만 달러에 달할 것으로 예측됩니다. 이 보고서는 현재 시장 역학에 대한 상세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

직접 작용 경구용 항응고제(DOAC) 장치는 직접 작용 경구용 항응고제를 사용하는 환자의 항응고 수준을 모니터링하여 안전하고 효과적인 치료 결과를 보장하기 위해 고안된 특수 진단 도구입니다. 특히 뇌졸중 예방, 정맥혈전색전증 관리, 수술 후 치료에서 응고 상태를 실시간으로 정확하게 파악하여 임상적 의사결정에 중요한 역할을 합니다.

응고 검사는 치료의 정확성을 높이고, 부작용을 최소화하며, 병원, 외래 센터, 재택치료의 모든 단계에서 환자의 맞춤 치료를 지원하는 데 필수적입니다. 분석 민감도, 기기 휴대성, 디지털 연결성의 발전으로 진단 효율성이 향상되어 급성기 및 만성기 치료 경로 모두에서 이러한 시스템의 유용성이 확대되고 있습니다. 일상적인 임상 워크플로우에 통합하면 환자 결과 개선, 모니터링 간소화, 전반적인 의료 비용 최적화에 기여할 수 있습니다.

직접 작용 경구용 항응고제(DOAC) 기기 시장 보고서 하이라이트

용도별로는 뇌졸중 예방 분야가 2024년 시장을 주도했으며, 이는 주로 심방세동 및 항응고 요법을 필요로 하는 기타 심혈관 질환의 유병률 증가에 기인합니다.

최종 사용자별로는 병원이 급성 혈전 사건과 만성 항응고 요법을 종합적으로 관리하는 주요 의료 시설로 기능하고 있기 때문에 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예측됩니다.

북미는 정교한 의료 인프라, 높은 혈전색전증 질환 부담, 의료 환경 전반에서 직접 작용 경구용 항응고제의 광범위한 임상 적용으로 인해 2024년 DOAC 기기 시장에서 가장 큰 매출 점유율을 차지했습니다.

아시아태평양 시장은 의료비 증가, 응고장애에 대한 인식 증가, 예방의학 및 개인맞춤형 치료로의 전환을 배경으로 안정적인 성장이 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 인사이트

  • 시장 현황
  • 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTEL 분석
  • 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 동향
  • 밸류체인 분석

제5장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 제품 유형별

  • 주요 조사 결과
  • 서론
  • Xa 인자 억제제
  • 직접 트롬빈 억제제

제6장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 질환 적응증별

  • 주요 조사 결과
  • 서론
  • 심방세동
  • 심부정맥 혈전증(DVT)
  • 폐색전증(PE)
  • 심장 발작
  • 수술후 혈전 예방
  • 기타

제7장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 용도별

  • 주요 조사 결과
  • 서론
  • 뇌졸중 예방
  • 정맥혈전 색전증 예방
  • 급성 혈전증 치료
  • 장기 예방
  • 기타 용도

제8장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 환자층별

  • 주요 조사 결과
  • 서론
  • 소아
  • 성인
  • 고령자

제9장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 최종사용자별

  • 주요 조사 결과
  • 서론
  • 병원
  • 외래수술센터(ASC)
  • 전문 클리닉
  • 홈케어 환경
  • 기타

제10장 세계의 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 직접 작용 경구용 항응고제(DOAC) 디바이스 시장 평가 : 지역별, 2020년-2034년
  • 북미
    • 북미 : 제품 유형별, 2020-2034년
    • 북미 : 질환별, 2020-2034년
    • 북미 : 용도별, 2020-2034년
    • 북미 : 환자층별, 2020-2034년
    • 북미 : 최종사용자별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 제품 유형별, 2020-2034년
    • 유럽 : 질환별, 2020-2034년
    • 유럽 : 용도별, 2020-2034년
    • 유럽 : 환자층별, 2020-2034년
    • 유럽 : 최종사용자별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 제품 유형별, 2020-2034년
    • 아시아태평양 : 질환별, 2020년-2034년
    • 아시아태평양 : 용도별, 2020-2034년
    • 아시아태평양 : 환자층별, 2020-2034년
    • 아시아태평양 : 최종사용자별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 제품 유형별, 2020-2034년
    • 중동 및 아프리카 : 질환별, 2020년-2034년
    • 중동 및 아프리카 : 용도별, 2020-2034년
    • 중동 및 아프리카 : 환자층별, 2020-2034년
    • 중동 및 아프리카 : 최종사용자별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 제품 유형별, 2020-2034년
    • 라틴아메리카 : 질환별, 2020년-2034년
    • 라틴아메리카 : 용도별, 2020-2034년
    • 라틴아메리카 : 환자층별, 2020-2034년
    • 라틴아메리카 : 최종사용자별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제11장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제12장 기업 개요

  • Siemens Healthineers
  • Abbott Laboratories
  • Roche Diagnostics
  • Sysmex Corporation
  • Instrumentation Laboratory(Werfen)
  • Nihon Kohden Corporation
  • Diagnostica Stago
  • Coag-Sense
  • HemoSonics
  • Sekisui Medical Co., Ltd.
  • Grifols S.A.
  • Helena Laboratories Corporation
LSH 25.07.10

The direct oral anticoagulants device market size is expected to reach USD 64.83 Billion by 2034, according to a new study by Polaris Market Research. The report "Direct Oral Anticoagulants (DOACs) Device Market Share, Size, Trends, Industry Analysis Report: By Product Type, By Disease Indication, By Application, By Patient Demographic, By End User, and By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Direct Oral Anticoagulants (DOACs) Device coagulation devices are specialized diagnostic tools designed to monitor anticoagulation levels in patients using direct oral anticoagulants, ensuring safe and effective therapeutic outcomes. These devices play a critical role in clinical decision-making by providing accurate, real-time insights into coagulation status, particularly in stroke prevention, venous thromboembolism management, and post-surgical care.

They are essential for improving treatment precision, minimizing adverse events, and supporting individualized patient care across hospitals, ambulatory centers, and homecare settings. Advancements in assay sensitivity, device portability, and digital connectivity are enhancing diagnostic efficiency and expanding the utility of these systems in both acute and chronic care pathways. Their integration into routine clinical workflows contributes to better patient outcomes, streamlined monitoring, and overall healthcare cost optimization.

Direct Oral Anticoagulants (DOACs) Device Market Report Highlights

In terms of application, the stroke prevention segment led the market in 2024, primarily due to rising prevalence of atrial fibrillation and other cardiovascular conditions requiring anticoagulation therapy.

In terms of end user, the hospitals are expected to register the highest CAGR during the forecast period, as they serve as the primary healthcare setting for comprehensive management of both acute thrombotic events and chronic anticoagulation requirements.

North America captured the largest revenue share in the DOAC device market in 2024, owing to its sophisticated healthcare infrastructure, high thromboembolic disease burden, and widespread clinical adoption of direct oral anticoagulants across care settings.

The Asia Pacific market is anticipated to demonstrate consistent growth, fueled by increasing healthcare expenditure, greater awareness of coagulation disorders, and a progressive transition toward preventive care and personalized treatment approaches.

A few global key market players include Siemens Healthineers, Abbott Laboratories, Roche Diagnostics, Sysmex Corporation, Instrumentation Laboratory (Werfen), Nihon Kohden Corporation, Diagnostica Stago, Coag-Sense, HemoSonics, Sekisui Medical Co., Ltd., Grifols S.A., and Helena Laboratories Corporation.

Polaris Market Research has segmented the market report on the basis of product type, disease indication, application, patient demographic, end user, and region:

By Product Type Outlook (Revenue, USD Billion, 2020-2034)

Factor Xa Inhibitors

Direct Thrombin Inhibitors

By Disease Indication Outlook (Revenue, USD Billion, 2020-2034)

Atrial Fibrillation

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Heart Attacks

Post-Surgical Thromboprophylaxis

Others

By Application Outlook (Revenue, USD Billion, 2020-2034)

Stroke Prevention

Venous Thromboembolism Prevention

Treatment of Acute Thrombotic Events

Long-Term Prophylaxis

Other Application

By Patient Demographic Outlook (Revenue, USD Billion, 2020-2034)

Paediatric

Adult

Geriatric

By End User Outlook (Revenue, USD Billion, 2020-2034)

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Homecare Settings

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Direct Oral Anticoagulants (DOACs) Device Market Insights

  • 4.1. Direct Oral Anticoagulants (DOACs) Device Market - Market Snapshot
  • 4.2. Direct Oral Anticoagulants (DOACs) Device Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Global Burden of Thromboembolic Disorders
      • 4.2.1.2. Aging Global Population with High Cardiovascular Risk
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Advanced Diagnostic Devices
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Direct Oral Anticoagulants (DOACs) Device Market Trends
  • 4.6. Value Chain Analysis

5. Global Direct Oral Anticoagulants (DOACs) Device Market, by Product Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
  • 5.3. Factor Xa Inhibitors
    • 5.3.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Factor Xa Inhibitors, by Region, 2020-2034 (USD Billion)
  • 5.4. Direct Thrombin Inhibitors
    • 5.4.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Direct Thrombin Inhibitors, by Region, 2020-2034 (USD Billion)

6. Global Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
  • 6.3. Atrial Fibrillation
    • 6.3.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Atrial Fibrillation, by Region, 2020-2034 (USD Billion)
  • 6.4. Deep Vein Thrombosis (DVT)
    • 6.4.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Deep Vein Thrombosis (DVT), by Region, 2020-2034 (USD Billion)
  • 6.5. Pulmonary Embolism (PE)
    • 6.5.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Pulmonary Embolism (PE), by Region, 2020-2034 (USD Billion)
  • 6.6. Heart Attacks
    • 6.6.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Heart Attacks, by Region, 2020-2034 (USD Billion)
  • 6.7. Post-Surgical Thromboprophylaxis
    • 6.7.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Post-Surgical Thromboprophylaxis, by Region, 2020-2034 (USD Billion)
  • 6.8. Others
    • 6.8.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Direct Oral Anticoagulants (DOACs) Device Market, by Application

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
  • 7.3. Stroke Prevention
    • 7.3.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Stroke Prevention, by Region, 2020-2034 (USD Billion)
  • 7.4. Venous Thromboembolism Prevention
    • 7.4.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Venous Thromboembolism Prevention, by Region, 2020-2034 (USD Billion)
  • 7.5. Treatment of Acute Thrombotic Events
    • 7.5.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Treatment of Acute Thrombotic Events, by Region, 2020-2034 (USD Billion)
  • 7.6. Long-Term Prophylaxis
    • 7.6.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Long-Term Prophylaxis, by Region, 2020-2034 (USD Billion)
  • 7.7. Other Application
    • 7.7.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Other Application, by Region, 2020-2034 (USD Billion)

8. Global Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
  • 8.3. Paediatric
    • 8.3.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Paediatric, by Region, 2020-2034 (USD Billion)
  • 8.4. Adult
    • 8.4.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Adult, by Region, 2020-2034 (USD Billion)
  • 8.5. Geriatric
    • 8.5.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Geriatric, by Region, 2020-2034 (USD Billion)

9. Global Direct Oral Anticoagulants (DOACs) Device Market, by End User

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
  • 9.3. Hospitals
    • 9.3.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Hospitals, by Region, 2020-2034 (USD Billion)
  • 9.4. Ambulatory Surgical Centers
    • 9.4.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Ambulatory Surgical Centers, by Region, 2020-2034 (USD Billion)
  • 9.5. Specialty Clinics
    • 9.5.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Specialty Clinics, by Region, 2020-2034 (USD Billion)
  • 9.6. Homecare Settings
    • 9.6.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Homecare Settings, by Region, 2020-2034 (USD Billion)
  • 9.7. Others
    • 9.7.1. Global Direct Oral Anticoagulants (DOACs) Device Market, by Others, by Region, 2020-2034 (USD Billion)

10. Global Direct Oral Anticoagulants (DOACs) Device Market, by Geography

  • 10.1. Key Findings
  • 10.2. Introduction
    • 10.2.1. Direct Oral Anticoagulants (DOACs) Device Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 10.3. Direct Oral Anticoagulants (DOACs) Device Market - North America
    • 10.3.1. North America: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
    • 10.3.2. North America: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
    • 10.3.3. North America: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
    • 10.3.4. North America: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
    • 10.3.5. North America: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.3.6. Direct Oral Anticoagulants (DOACs) Device Market - U.S.
      • 10.3.6.1. U.S.: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.3.6.2. U.S.: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.3.6.3. U.S.: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.3.6.4. U.S.: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.3.6.5. U.S.: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.3.7. Direct Oral Anticoagulants (DOACs) Device Market - Canada
      • 10.3.7.1. Canada: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.3.7.2. Canada: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.3.7.3. Canada: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.3.7.4. Canada: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.3.7.5. Canada: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
  • 10.4. Direct Oral Anticoagulants (DOACs) Device Market - Europe
    • 10.4.1. Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
    • 10.4.2. Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
    • 10.4.3. Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
    • 10.4.4. Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
    • 10.4.5. Europe: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.6. Direct Oral Anticoagulants (DOACs) Device Market - UK
      • 10.4.6.1. UK: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.6.2. UK: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.6.3. UK: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.6.4. UK: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.6.5. UK: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.7. Direct Oral Anticoagulants (DOACs) Device Market - France
      • 10.4.7.1. France: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.7.2. France: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.7.3. France: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.7.4. France: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.7.5. France: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.8. Direct Oral Anticoagulants (DOACs) Device Market - Germany
      • 10.4.8.1. Germany: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.8.2. Germany: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.8.3. Germany: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.8.4. Germany: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.8.5. Germany: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.9. Direct Oral Anticoagulants (DOACs) Device Market - Italy
      • 10.4.9.1. Italy: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.9.2. Italy: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.9.3. Italy: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.9.4. Italy: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.9.5. Italy: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.10. Direct Oral Anticoagulants (DOACs) Device Market - Spain
      • 10.4.10.1. Spain: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.10.2. Spain: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.10.3. Spain: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.10.4. Spain: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.10.5. Spain: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.11. Direct Oral Anticoagulants (DOACs) Device Market - Netherlands
      • 10.4.11.1. Netherlands: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.11.2. Netherlands: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.11.3. Netherlands: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.11.4. Netherlands: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.11.5. Netherlands: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.12. Direct Oral Anticoagulants (DOACs) Device Market - Russia
      • 10.4.12.1. Russia: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.12.2. Russia: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.12.3. Russia: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.12.4. Russia: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.12.5. Russia: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.4.13. Direct Oral Anticoagulants (DOACs) Device Market - Rest of Europe
      • 10.4.13.1. Rest of Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.4.13.2. Rest of Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.4.13.3. Rest of Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.4.13.4. Rest of Europe: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.4.13.5. Rest of Europe: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
  • 10.5. Direct Oral Anticoagulants (DOACs) Device Market - Asia Pacific
    • 10.5.1. Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
    • 10.5.2. Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
    • 10.5.3. Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
    • 10.5.4. Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
    • 10.5.5. Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.6. Direct Oral Anticoagulants (DOACs) Device Market - China
      • 10.5.6.1. China: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.6.2. China: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.6.3. China: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.6.4. China: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.6.5. China: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.7. Direct Oral Anticoagulants (DOACs) Device Market - India
      • 10.5.7.1. India: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.7.2. India: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.7.3. India: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.7.4. India: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.7.5. India: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.8. Direct Oral Anticoagulants (DOACs) Device Market - Malaysia
      • 10.5.8.1. Malaysia: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.8.2. Malaysia: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.8.3. Malaysia: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.8.4. Malaysia: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.8.5. Malaysia: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.9. Direct Oral Anticoagulants (DOACs) Device Market - Japan
      • 10.5.9.1. Japan: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.9.2. Japan: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.9.3. Japan: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.9.4. Japan: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.9.5. Japan: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.10. Direct Oral Anticoagulants (DOACs) Device Market - Indonesia
      • 10.5.10.1. Indonesia: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.10.2. Indonesia: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.10.3. Indonesia: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.10.4. Indonesia: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.10.5. Indonesia: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.11. Direct Oral Anticoagulants (DOACs) Device Market - South Korea
      • 10.5.11.1. South Korea: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.11.2. South Korea: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.11.3. South Korea: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.11.4. South Korea: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.11.5. South Korea: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.12. Direct Oral Anticoagulants (DOACs) Device Market - Australia
      • 10.5.12.1. Australia: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.12.2. Australia: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.12.3. Australia: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.12.4. Australia: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.12.5. Australia: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.5.13. Direct Oral Anticoagulants (DOACs) Device Market - Rest of Asia Pacific
      • 10.5.13.1. Rest of Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.5.13.2. Rest of Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.5.13.3. Rest of Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.5.13.4. Rest of Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.5.13.5. Rest of Asia Pacific: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
  • 10.6. Direct Oral Anticoagulants (DOACs) Device Market - Middle East & Africa
    • 10.6.1. Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
    • 10.6.2. Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
    • 10.6.3. Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
    • 10.6.4. Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
    • 10.6.5. Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.6.6. Direct Oral Anticoagulants (DOACs) Device Market - Saudi Arabia
      • 10.6.6.1. Saudi Arabia: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.6.6.2. Saudi Arabia: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.6.6.3. Saudi Arabia: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.6.6.4. Saudi Arabia: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.6.6.5. Saudi Arabia: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.6.7. Direct Oral Anticoagulants (DOACs) Device Market - UAE
      • 10.6.7.1. UAE: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.6.7.2. UAE: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.6.7.3. UAE: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.6.7.4. UAE: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.6.7.5. UAE: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.6.8. Direct Oral Anticoagulants (DOACs) Device Market - Israel
      • 10.6.8.1. Israel: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.6.8.2. Israel: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.6.8.3. Israel: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.6.8.4. Israel: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.6.8.5. Israel: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.6.9. Direct Oral Anticoagulants (DOACs) Device Market - South Africa
      • 10.6.9.1. South Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.6.9.2. South Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.6.9.3. South Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.6.9.4. South Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.6.9.5. South Africa: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.6.10. Direct Oral Anticoagulants (DOACs) Device Market - Rest of Middle East & Africa
      • 10.6.10.1. Rest of Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.6.10.2. Rest of Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.6.10.3. Rest of Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.6.10.4. Rest of Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.6.10.5. Rest of Middle East & Africa: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
  • 10.7. Direct Oral Anticoagulants (DOACs) Device Market - Latin America
    • 10.7.1. Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
    • 10.7.2. Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
    • 10.7.3. Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
    • 10.7.4. Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
    • 10.7.5. Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.7.6. Direct Oral Anticoagulants (DOACs) Device Market - Mexico
      • 10.7.6.1. Mexico: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.7.6.2. Mexico: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.7.6.3. Mexico: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.7.6.4. Mexico: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.7.6.5. Mexico: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.7.7. Direct Oral Anticoagulants (DOACs) Device Market - Brazil
      • 10.7.7.1. Brazil: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.7.7.2. Brazil: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.7.7.3. Brazil: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.7.7.4. Brazil: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.7.7.5. Brazil: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.7.8. Direct Oral Anticoagulants (DOACs) Device Market - Argentina
      • 10.7.8.1. Argentina: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.7.8.2. Argentina: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.7.8.3. Argentina: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.7.8.4. Argentina: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.7.8.5. Argentina: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)
    • 10.7.9. Direct Oral Anticoagulants (DOACs) Device Market - Rest of Latin America
      • 10.7.9.1. Rest of Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Product Type, 2020-2034 (USD Billion)
      • 10.7.9.2. Rest of Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Disease Indication, 2020-2034 (USD Billion)
      • 10.7.9.3. Rest of Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Application, 2020-2034 (USD Billion)
      • 10.7.9.4. Rest of Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by Patient Demographic, 2020-2034 (USD Billion)
      • 10.7.9.5. Rest of Latin America: Direct Oral Anticoagulants (DOACs) Device Market, by End User, 2020-2034 (USD Billion)

11. Competitive Landscape

  • 11.1. Expansion and Acquisition Analysis
    • 11.1.1. Expansion
    • 11.1.2. Acquisitions
  • 11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

  • 12.1. Siemens Healthineers
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Benchmarking
    • 12.1.4. Recent Development
  • 12.2. Abbott Laboratories
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Benchmarking
    • 12.2.4. Recent Development
  • 12.3. Roche Diagnostics
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Benchmarking
    • 12.3.4. Recent Development
  • 12.4. Sysmex Corporation
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Benchmarking
    • 12.4.4. Recent Development
  • 12.5. Instrumentation Laboratory (Werfen)
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Benchmarking
    • 12.5.4. Recent Development
  • 12.6. Nihon Kohden Corporation
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Benchmarking
    • 12.6.4. Recent Development
  • 12.7. Diagnostica Stago
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Benchmarking
    • 12.7.4. Recent Development
  • 12.8. Coag-Sense
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Benchmarking
    • 12.8.4. Recent Development
  • 12.9. HemoSonics
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Benchmarking
    • 12.9.4. Recent Development
  • 12.10. Sekisui Medical Co., Ltd.
    • 12.10.1. Company Overview
    • 12.10.2. Financial Performance
    • 12.10.3. Product Benchmarking
    • 12.10.4. Recent Development
  • 12.11. Grifols S.A.
    • 12.11.1. Company Overview
    • 12.11.2. Financial Performance
    • 12.11.3. Product Benchmarking
    • 12.11.4. Recent Development
  • 12.12. Helena Laboratories Corporation
    • 12.12.1. Company Overview
    • 12.12.2. Financial Performance
    • 12.12.3. Product Benchmarking
    • 12.12.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제